Previous close | 17.50 |
Open | 17.40 |
Bid | 0.00 x 1100 |
Ask | 0.00 x 1000 |
Day's range | 17.37 - 20.95 |
52-week range | 13.84 - 126.51 |
Volume | |
Avg. volume | 1,486,980 |
Market cap | 778.701M |
Beta (5Y monthly) | 0.69 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 13 Dec 2012 |
1y target est | N/A |
NEW YORK, December 04, 2021--Second paragraph of release dated December 3, 2021, should read: The lawsuit alleges that... (instead of The complaint, filed on January 5, 2021, alleges that...)
SAN DIEGO & AUSTIN, Texas, October 29, 2021--Cassava Sciences, Inc. (SAVA) Accused of Falsely Touting the Viability and Efficacy of its Lead Drug Candidate
LOS ANGELES, October 26, 2021--Glancy Prongay & Murray LLP ("GPM"), announces that it has filed a class action lawsuit in the United States District Court for the Western District of Texas captioned Rao v. Cassava Sciences, Inc., et al., (Case No. 1:21-cv-00971) on behalf of persons and entities that purchased or otherwise acquired Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) securities, and/or sold (wrote) Cassava put options, between September 14, 2020 and August 27, 2021